CD4 and melanoma: In line with our finding, a recent report showed a long-term clinical benefit in patients with melanoma who were previously vaccinated 10 years ago with a melanoma CD4+ helper peptide vaccine as adjuvant therapy,34 highlighting the importance of developing CD4+ T immunological memory to improve cancer vaccine efficacy.61